VISARIX Trademark

Trademark Overview

On Thursday, September 26, 2002, a trademark application was filed for VISARIX with the United States Patent and Trademark Office. The USPTO has given the VISARIX trademark a serial number of 76454661. The federal status of this trademark filing is ABANDONED - NO STATEMENT OF USE FILED as of Monday, April 20, 2009. This trademark is owned by SmithKline Beecham Biologicals, S.A.. The VISARIX trademark is filed in the Pharmaceutical Products category with the following description:

vaccines for human use
visarix

General Information

Serial Number76454661
Word MarkVISARIX
Filing DateThursday, September 26, 2002
Status606 - ABANDONED - NO STATEMENT OF USE FILED
Status DateMonday, April 20, 2009
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing1000 - Typeset: Word(s) / letter(s) / number(s)
Published for Opposition DateTuesday, December 27, 2005

Trademark Statements

Goods and Servicesvaccines for human use

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateWednesday, October 9, 2002
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameGLAXOSMITHKLINE BIOLOGICALS S.A.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressRIXENSART B1330
BE
Party NameGLAXOSMITHKLINE BIOLOGICALS S.A.
Party Type12 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressB-1330 RIXENSART
BE
Party NameGLAXOSMITHKLINE BIOLOGICALS S.A.
Party Type11 - New Owner Before Publication
Legal Entity Type03 - Corporation
AddressB-1330 RIXENSART
BE
Party NameSmithKline Beecham Biologicals, S.A.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressB-1330 Rixensart
BE

Trademark Events

Event DateEvent Description
Monday, April 20, 2009ABANDONMENT NOTICE MAILED - NO USE STATEMENT FILED
Monday, April 20, 2009ABANDONMENT - NO USE STATEMENT FILED
Monday, August 18, 2008EXTENSION 5 GRANTED
Monday, August 18, 2008EXTENSION 5 FILED
Monday, August 18, 2008TEAS EXTENSION RECEIVED
Wednesday, March 19, 2008EXTENSION 4 GRANTED
Monday, February 25, 2008EXTENSION 4 FILED
Monday, February 25, 2008TEAS EXTENSION RECEIVED
Saturday, September 22, 2007EXTENSION 3 GRANTED
Tuesday, August 21, 2007EXTENSION 3 FILED
Tuesday, August 21, 2007TEAS EXTENSION RECEIVED
Tuesday, January 30, 2007EXTENSION 2 GRANTED
Tuesday, January 30, 2007EXTENSION 2 FILED
Tuesday, January 30, 2007TEAS EXTENSION RECEIVED
Tuesday, September 5, 2006EXTENSION 1 GRANTED
Tuesday, September 5, 2006EXTENSION 1 FILED
Tuesday, September 5, 2006TEAS EXTENSION RECEIVED
Tuesday, March 21, 2006NOA MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, December 27, 2005PUBLISHED FOR OPPOSITION
Wednesday, December 7, 2005NOTICE OF PUBLICATION
Tuesday, November 8, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Tuesday, November 8, 2005ASSIGNED TO LIE
Friday, October 21, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Friday, October 21, 2005PREVIOUS ALLOWANCE COUNT WITHDRAWN
Monday, February 28, 2005LAW OFFICE PUBLICATION REVIEW COMPLETED
Friday, February 25, 2005ASSIGNED TO LIE
Thursday, February 24, 2005APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, February 24, 2005AMENDMENT FROM APPLICANT ENTERED
Tuesday, February 15, 2005CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, February 15, 2005TEAS RESPONSE TO OFFICE ACTION RECEIVED
Wednesday, August 18, 2004NON-FINAL ACTION MAILED
Tuesday, August 17, 2004PREVIOUS ALLOWANCE COUNT WITHDRAWN
Sunday, September 28, 2003APPROVED FOR PUB - PRINCIPAL REGISTER
Thursday, July 31, 2003TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, February 6, 2003NON-FINAL ACTION MAILED
Friday, January 31, 2003ASSIGNED TO EXAMINER

Related Keywords

visarix human vaccines